This formula was tested on data from nearly 100,000 people and might help prevent heart disease and save a lot of money — but it hasn’t been proven yet.
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim implies cost savings and prevention are demonstrated outcomes, but no metrics (e.g., event reduction, cost per patient) are provided. The language 'highlights the potential' is vague and unsupported by evidence in the abstract.
More Accurate Statement
“The multibiomarker analysis formula (MAF) was applied to screening data from over 95,000 patients from Cleveland Heart Lab and MDVIP, Inc., suggesting a potential pathway for atherosclerotic cardiovascular disease risk assessment and cost reduction that requires prospective validation.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Evidence from Studies
Supporting (1)
This study used a special formula (MAF) that looks at multiple health markers to predict heart disease risk, and they tested it on over 95,000 people — just like the claim says. It shows this method could help stop heart disease and save money.